The purpose of this study was to determine whether asthma control and reduced bronchial
hyperresponsiveness could be achieved and maintained at a lower dose of inhaled
corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent
subjects with persistent asthma
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate